SOR-C13 (TFA)
Product Specifications
UNSPSC Description
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity[1].
Target Antigen
TRP Channel
Type
Peptides
Related Pathways
Membrane Transporter/Ion Channel;Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sor-c13-tfa.html
Purity
99.18
Solubility
DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
Smiles
[Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg (TFA salt)]
Molecular Weight
1565.81 (free acid)
References & Citations
[1]S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397. |[2]Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P1651A/SOR-C13-TFA-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P1651A/SOR-C13-TFA-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items